Fidelity SPDR Advertisement
Home > Boards > US OTC > Medical - Drugs >

Entest BioMedical Inc. (ENTB)

ENTB RSS Feed
Add ENTB Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator 1-eye-jack, stockchaser64, d5wr59mfi8, PetePham
Search This Board:
Last Post: 12/20/2014 7:46:22 PM - Followers: 487 - Board type: Free - Posts Today: 0

Entest BioMedical Inc. (ENTB)

 


Share Structure:

as of = 10/24/2014

O/S = 2,405,570,000 

A/S = 6,000,000,000


ENTB Transfer Agent 

Securities Transfer Corporation 
2591 Dallas Parkway Suite 102 
Frisco, Texas 75034 

Fax: 469-633-0088 
Phone: 469-633-0101 
www.stctransfer.com 

 

 

http://www.entb.net


 

 

 

 

 

Company Information:                                                      
4700 Spring Street, Suite 304
La Mesa, Calif. 91942
Telephone: 619-644-3344
Fax: 619-330-2328
E-mail:
info@EntestBio.com

Web site: www.EntestBio.com

 

CIK 0001449447
 

ImenVax (TM)

Immuno-Therapeutic Cancer Treatment for Canines


 

In the encapsulated ImenVax™ device, a "cocktail" of integral immuno-catalysts are enclosed. From this ImenVax™ device immuno-catalysts are released which activate the patient's immune cell. These immune cells carry on their normal course of activity by entering the lymph nodes and cause T-Cell adaptation. These T-Cells are what attack and kill the tumor. (Figure 1)
 


Entest BioMedical Inc. (OTCQB: ENTB)is a majority owned subsidiary of Bio-Matrix Scientific Group Inc (OTCQB: BMSN). The Company is involved with the development of stem cell therapy treatments for Chronic Obstructive Pulmonary Disease (COPD), cancer immuno-therapies, testing procedures for diabetes and stem cell research applications for diabetes and other illnesses. The Company also is involved with medical device development (including stem cell extraction instrumentation).

Currently, Entest is focused on research and development in areas of COPD and Immuno-Therapeutic Cancer Vaccines. The Company sees applications for its patent pending technologies in both human and animal venues.

Immuno-therapeutic treatment of cancer - The patent pending Entest application involves perfecting the use of cell lines for sustained release of immunologically relevant cytokines for maximum anti-tumor immune responses in treating cancer. The treatment process itself will utilize an implantable encapsulation device as the vaccine delivery system and the initial focus will be treatment of cancer in canines. This canine cancer treatment may also provide clinical support for expansion into human cancer treatment.

Chronic Obstructive Pulmonary Disease -There is currently no cure for COPD and therapy is limited to management of the condition and its symptoms. Over the next 5 years, it is estimated that over $170 billion will be spent on treating COPD in the United States. Entest believes its COPD treatment, which utilizes patent pending adult stem cell therapy coupled with photoceutical device enhancement, has the potential to reverse COPD related lung damage as well as alleviate symptoms.

Entest BioMedical was founded for the purpose of providing excellence in biotechnology research (including adult stem cell regenerative treatment). Our objectives go beyond developing single products and procedures. Our mission is to discover and develop new procedures, treatments and medical devices that improve the quality of life. Our efforts revolve around a business focus of developing leading research and technology. Ongoing R&D is paramount to us in developing products and procedures with purpose, products and services that serve the present and help shape the future.

 

Management: 

David R. Koos, PhD, DBA - Chairman and CEO, Secretary, Acting CFO
Feng Lin, MD, PhD - Director of Research
Marilyn Panahi - Director of Quality Assurance

 

http://www.entb.net

 

 

 

 

 

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
ENTB
Current Price
Volume:
Bid Ask Day's Range
Wiki
ENTB News: Annual Report (10-k) 11/26/2014 11:18:00 AM
ENTB News: Current Report Filing (8-k) 07/14/2014 04:36:32 PM
ENTB News: Quarterly Report (10-q) 07/09/2014 03:42:59 PM
PostSubject
#36034  Sticky Note Entest BioMedical's ImenVax(TM) Cancer Vaccine Appears to Slow PetePham 10/26/14 10:28:49 PM
#34823  Sticky Note What's he running? ENTB is a SKIPPERANDGILLIGAN 05/20/14 11:03:15 AM
#36231   Thanks for the laugh ?? Brakeman 12/20/14 07:46:22 PM
#36230   CHIRP CHIRP CHIRP Kinda figured this board would be angelicsatan666 12/20/14 10:23:49 AM
#36229   Keep loading here, you will have a stack sizzleweed 12/18/14 06:33:31 PM
#36228   Cramer just talking about Regeneron, who had an sizzleweed 12/18/14 06:29:49 PM
#36227   The "KOOS and CRONIES SYNDICATE" still runnin this angelicsatan666 12/18/14 04:55:20 PM
#36224   Thanks sizzle! Kbro13 12/18/14 01:56:11 PM
#36223   It cracked a penny in March 13. I sizzleweed 12/17/14 04:57:59 PM
#36222   I hope you are not smoking your board bucks2pennies 12/17/14 02:18:52 PM
#36221   Welcome to the 20 milly club KBRO. I sizzleweed 12/17/14 01:52:55 PM
#36219   New direction..believe much more viable and credible with JokersWild12 12/14/14 12:20:07 PM
#36218   What EVER happened to the "vet clinics" he angelicsatan666 12/13/14 08:39:23 AM
#36217   Motion forward. To da moon. $entb Meach2 12/11/14 11:29:33 PM
#36216   Downside is zip, up is huge! akakooper 12/11/14 03:58:24 PM
#36215   IMHO - you won't be sorry you did. Kbro13 12/11/14 03:38:41 PM
#36214   I caved and bought some 2s akakooper 12/11/14 03:18:56 PM
#36213   Not yet. Don't want to buy 2's but akakooper 12/11/14 02:48:52 PM
#36212   I have a line pass :) akakooper 12/11/14 02:45:04 PM
#36211   Are you already loaded-up? Kbro13 12/11/14 02:29:02 PM
#36210   lol. there are 124 million in front of SKIPPERANDGILLIGAN 12/11/14 02:04:27 PM
#36209   1's. akakooper 12/11/14 01:50:39 PM
#36208   2'S? Kbro13 12/11/14 01:32:49 PM
#36207   At .0001 akakooper 12/11/14 01:32:40 PM
#36206   1mil akakooper 12/11/14 01:31:52 PM
#36205   what is it for? Kbro13 12/11/14 01:29:50 PM
#36204   Can't get my ordered filled! akakooper 12/11/14 12:57:39 PM
#36203   Yes... I believe there is a plan in GM_FSJ 12/11/14 10:57:12 AM
#36202   No mention of Entest...Isn't Christine Ichim the Director JokersWild12 12/11/14 10:55:25 AM
#36201   http://www.marketwired.com/press-release/regen-biopharma-presented-novel-therape GM_FSJ 12/11/14 09:41:43 AM
#36200   Saturday, December 6, 2014, 5:30 PM-7:30 PM sizzleweed 12/10/14 06:44:14 PM
#36199   The Feds' approval process for medical design as bucks2pennies 12/10/14 10:01:13 AM
#36198   Thats true...The good thing is this biotech has JokersWild12 12/10/14 09:41:10 AM
#36197   Anyone thinking that ENTB does not belong is bucks2pennies 12/10/14 09:12:11 AM
#36196   Everyone needs to read, huge shot of credibility Rk3 12/09/14 06:19:50 PM
#36194   ENTB is talking. Not loud but if bucks2pennies 12/09/14 04:23:04 PM
#36193   Yes, the research needs to get tied to JokersWild12 12/08/14 09:54:04 AM
#36192   Wouldn't you expect a little interest bubble in bucks2pennies 12/08/14 08:44:54 AM
#36191   AMERICAN SOCIETY OF HEMATOLOGY sizzleweed 12/07/14 11:03:37 PM
#36190   .0001 is WAYYYYYYYYYY overpriced for this POS NO BID--then angelicsatan666 12/06/14 07:12:01 PM
#36189   no bid. eeeeek SKIPPERANDGILLIGAN 12/05/14 01:53:24 PM
#36188   Let it be...ENTB Highlandmike 12/04/14 09:58:49 PM
#36187   you are right, 10 cents a share minimum. sizzleweed 12/04/14 05:52:12 PM
#36186   Lets hope its more than ONE CENT. With JokersWild12 12/04/14 03:21:43 PM
#36185   I believe with Christine Ichim at the helm, sizzleweed 12/04/14 01:55:49 PM
#36184   notice on the bottom of my recent post...the gotinearly 12/04/14 10:16:25 AM
#36183   This conference will have an affect on how bucks2pennies 12/04/14 08:44:26 AM
#36182   Hello Sizzleweed panda11 12/04/14 02:08:43 AM
#36181   From upcoming conference... gotinearly 12/03/14 02:27:48 PM
#36180   Hahahahahahaha--"...buy it by the millions" BUT SELL IT angelicsatan666 12/03/14 07:52:31 AM
#36179   It's a tri fecta moment tomorrow!!! prof81 12/02/14 08:10:29 PM
#36178   I was thinking the same thing... ENTB is GM_FSJ 12/02/14 07:37:06 PM
PostSubject